Loading clinical trials...
Loading clinical trials...
A PHASE 2B, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS, DIPHTHERIA, AND ACELLULAR PERTUSSIS VACCINE (TDAP) IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE
Conditions
Interventions
Multivalent Group B streptococcus vaccine
Tetanus, diphtheria, and acellular pertussis vaccine
+1 more
Locations
12
United States
Alliance for Multispecialty Research, LLC
Newton, Kansas, United States
Quality Clinical Research, Inc
Omaha, Nebraska, United States
Alliance for Multispecialty Research, LLC
Las Vegas, Nevada, United States
Accellacare - Raleigh
Raleigh, North Carolina, United States
Accellacare - Wilmington
Wilmington, North Carolina, United States
PriMED Clinical Research
Dayton, Ohio, United States
Start Date
August 12, 2022
Primary Completion Date
April 27, 2023
Completion Date
April 27, 2023
Last Updated
May 24, 2024
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions